Coreline Soft, a South Korea-based medical AI company specialising in thoracic imaging, announced on Saturday that it is collaborating with INFINITT North America, a developer of enterprise imaging solutions, to bridge the gap between advanced technology and daily clinical practice.
The partners have successfully deployed a fully automated, 'zero-click' AI reading solution now live in US radiology practices.
According to the companies, this deep-embed integration allows radiologists to access AI-powered insights directly within their familiar INFINITT PACS environment -- eliminating the need for extra clicks, new logins, or workflow interruptions.
By embedding Coreline's AVIEW AI platform directly into the INFINITT PACS, the integration automates coronary artery calcium (CAC) scoring, enhances lung nodule detection, and reduces case reading times.
To further support the US market, Coreline Soft has launched the INFINITT Integration Suite, a dedicated package for INFINITT users that enables rapid deployment of AI modules, supports CPT-based reimbursement, and delivers a hands-free experience for clinicians.
ALK secures EU approval for EURneffy 1 mg as needle-free adrenaline option for children
4DMedical secures EU approval for CT:VQ as EUR83m funding fuels European expansion
AstraZeneca's tozorakimab meets primary endpoints in two Phase III COPD trials
Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator
Akeso's Phase II trials of AK146D1 and AK138D1 approved in China
UCB selects PANTHERx Rare to distribute KYGEVVI for TK2d
Roche launches new test to help clinicians treat patients with respiratory infections
GSK secures Japan Orphan Drug status for lung cancer ADC
Dizal meets primary endpoint in Phase 3 study of ZEGFROVY (sunvozertinib) monotherapy
bioMérieux secures IVDR CE marking for respiratory diagnostic panels in Europe
Avacta opens Phase 1 trial for AVA6103 cancer therapy in US
IDEAYA Biosciences enrols first patient in Phase 1 trial of PRMT5 inhibitor IDE892
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation